News
SNBIF
9.40
NaN%
--
SanBio Co. Announces International Offering to Fund Key Clinical Trials
TipRanks · 11/06 14:52
SanBio Co. Announces International Share Offering to Fund Regenerative Medicine Expansion
TipRanks · 11/06 08:27
SanBio’s AKUUGO Gains Approval for Launch, Eyes Global Expansion
TipRanks · 10/16 11:52
SanBio Co. Reports Losses Amid R&D Investments
Barchart · 10/04 22:54
SanBio Awaits Regulatory Decision on AKUUGO Suspension
TipRanks · 10/02 06:52
SanBio Co (SNBIF) Gets a Sell from Jefferies
TipRanks · 09/26 12:45
Weekly Report: what happened at SNBIF last week (0908-0912)?
Weekly Report · 09/15 11:48
SanBio Revises Earnings Forecast, Projects Greater Loss
TipRanks · 09/12 07:05
SanBio Co. Reports Financial Adjustments Amid Currency Fluctuations
TipRanks · 09/12 07:04
SanBio Co. Reports Increased Losses in First Half of 2025
TipRanks · 09/12 07:04
Weekly Report: what happened at SNBIF last week (0901-0905)?
Weekly Report · 09/08 11:50
Weekly Report: what happened at SNBIF last week (0825-0829)?
Weekly Report · 09/01 11:45
Weekly Report: what happened at SNBIF last week (0818-0822)?
Weekly Report · 08/25 11:58
Weekly Report: what happened at SNBIF last week (0811-0815)?
Weekly Report · 08/18 11:48
Weekly Report: what happened at SNBIF last week (0804-0808)?
Weekly Report · 08/11 11:58
Weekly Report: what happened at SNBIF last week (0728-0801)?
Weekly Report · 08/04 12:00
Weekly Report: what happened at SNBIF last week (0721-0725)?
Weekly Report · 07/28 12:01
Weekly Report: what happened at SNBIF last week (0714-0718)?
Weekly Report · 07/21 11:49
SanBio Secures Credit Line for AKUUGO Commercialization
TipRanks · 07/18 07:00
More
Webull provides a variety of real-time SNBIF stock news. You can receive the latest news about Sanbio Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SNBIF
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).